<DOC>
	<DOCNO>NCT02761863</DOCNO>
	<brief_summary>This prospective study evaluate effect expression CD74 VEGF outcome treatment patient malignant pleural mesothelioma receive Pemetrexed/Platinum protocol . The paraffin block patient test CD74 VEGF start treatment use IHC result correlate outcome treatment evaluation .</brief_summary>
	<brief_title>Effect Expression CD74 VEGF Outcome Treatment Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>1 . Histologic cytologic diagnosis malignant pleural Mesothelioma 2 . No prior chemotherapy . 3 . ECOG le equal 2 . 4 . Measurable disease accord requirement SWOG criterion . 5 . Age ≥ 19 year . 6 . Estimated life expectancy least 12 week . 7 . Adequate bone marrow reserve ( white blood cell [ WBC ] ≥ 3.5 × 109 /L , neutrophils ≥ 1.5 × 109 /L , platelet ≥ 100 × 109 /L , hemoglobin ≥ 9.0 gm/dL ) . 1 . Presence central nervous system metastasis . 2 . Inadequate liver function ( bilirubin &gt; 1.5 time upper normal limit [ UNL ] alanine transaminase [ ALT ] aspartate transaminase [ AST ] &gt; 3.0 UNL 5.0 UNL presence hepatic metastasis ) . 3 . Inadequate renal function ( creatinine &gt; 1.25 time UNL , creatinine clearance &lt; 50mL/min ) . 4 . Serious concomitant systemic disorder incompatible study . 5 . Second primary malignancy ( except situ carcinoma cervix , adequately treat basal cell carcinoma skin , T1 vocal cord cancer remission , prior malignancy treat 5 year prior enrollment without recurrence ) . 6 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>CD 74</keyword>
	<keyword>VEGF</keyword>
</DOC>